Publications by authors named "T Venesio"

Article Synopsis
  • Archive tissues are valuable for molecular research but often suffer from degraded biomolecules like proteins, DNA, and RNA.
  • The study compares the effectiveness of nCounter Nanostring technology for quantifying mRNA in Bouin's fixed and paraffin-embedded (BFPE) tissues versus standard formalin-fixed and paraffin-embedded (FFPE) tissues.
  • Results indicate that Nanostring technology is more effective than qPCR and ddPCR methods in detecting target mRNA, yet RNA degradation still limits the accuracy of gene expression conclusions.
View Article and Find Full Text PDF

In recent years, immune checkpoint inhibitors have proved immense clinical progression in the treatment of certain cancers. The efficacy of immune checkpoint inhibitors is correlated with mismatch repair system deficiency and is exceptionally administered based exclusively on this biological mechanism independent of the cancer type. The promising effect of immune checkpoint inhibitors has left an increasing demand for analytical tools evaluating the mismatch repair status.

View Article and Find Full Text PDF

Introduction: Biomarker testing is mandatory for the clinical management of patients with advanced non-small cell lung cancer (NSCLC). Myriads of technical platforms are now available for biomarker analysis with differences in terms of multiplexing capability, analytical sensitivity, and turnaround time (TAT). We evaluated the technical performance of the diagnostic workflows of 24 representative Italian institutions performing molecular tests on a series of artificial reference specimens built to mimic routine diagnostic samples.

View Article and Find Full Text PDF

Background: The current therapeutic algorithm for Advanced Stage Melanoma comprises of alternating lines of Targeted and Immuno-therapy, mostly via Immune-Checkpoint blockade. While Comprehensive Genomic Profiling of solid tumours has been approved as a companion diagnostic, still no approved predictive biomarkers are available for Melanoma aside from BRAF mutations and the controversial Tumor Mutational Burden. This study presents the results of a Multi-Centre Observational Clinical Trial of Comprehensive Genomic Profiling on Target and Immuno-therapy treated advanced Melanoma.

View Article and Find Full Text PDF